Opdivo and Yervoy Patient Assistance: an application guide for practices
Bristol Myers Squibb runs patient assistance for Opdivo and Yervoy through a single enrollment form. It requires prescriber certification of the diagnosis and treatment plan, the patient’s consent and signature, and proof of household income. The two are frequently prescribed together, and each still needs its own enrollment.
Are you a patient? Start with the prescribing practice and use the official manufacturer link above for current program information. AlgoMeds cannot determine eligibility or check an application for you.
One application covers Opdivo and Yervoy
These two are commonly given as a combination regimen, so the same patient often needs both enrollments at once, and the form is the same document for each.
That is the unusual case where one clinical decision creates two applications that are genuinely identical in structure. The duplication is in the filing, not in the learning.
Because two applications for one patient run in parallel, small inconsistencies between them are easy to introduce and hard to spot on a manual review.
| Brand | Generic | Used for | How it is given |
|---|---|---|---|
| Opdivo | nivolumab | several solid tumors including melanoma, renal cell carcinoma and non-small cell lung cancer | Infused in the practice or infusion suite |
| Yervoy | ipilimumab | melanoma and several other advanced cancers, often in combination regimens | Infused in the practice or infusion suite |
Eligibility factors to verify
Bristol Myers Squibb sets the eligibility criteria for the Opdivo and Yervoy program and changes them, so the categories below are only the ones programs of this kind generally assess.They are not the criteria for this program, confirm current requirements onBristol Myers Squibb’s official program pagebefore telling a patient anything. We do not publish income thresholds for Opdivo and Yervoy here, because a stale number on a marketing page is how a practice ends up telling a patient the wrong thing.
- Insurance status, generally aimed at patients who are uninsured, or insured but unable to access the medication through their coverage.
- Household income against the program’s own published threshold, evidenced by documentation rather than attestation.
- Residency and prescriber licensure requirements set by the program.
- A prescription written for an indication the program covers, certified by the prescribing clinician.
What the application needs
A complete Opdivo and Yervoy application is assembled from the four parts below, and because Opdivo and Yervoy is infused in the practice or infusion suite, the part most likely to hold it up is the one this practice controls least. Missing any one of them is what sends a form back rather than forward.
| Part | Who owns it | What it contains |
|---|---|---|
| Prescriber section | Prescribing clinician | Diagnosis, treatment plan, prescribed regimen, prescriber credentials and NPI, and the certification signature. |
| Patient section | Patient or verified legal representative | Demographics, contact and shipping details, insurance status, household information, program consent and the patient’s signature. |
| Income documentation | Patient | Documentary evidence of household income, in whichever forms the program accepts. |
| Program-specific attachments | Practice | Whatever else this specific program requires. Requirements differ between programs and change over time. |
Where practices get stuck
Common workflow challenges for these programs:
- One clinical decision routinely creates two parallel applications for the same patient in the same week.
- The combination course is short and front-loaded, which compresses the time available to get an application through.
- Dosing intervals vary by indication, so the enrollment window a coordinator works against differs from patient to patient.
- Both are administered in the practice, so the assistance workflow has to reconcile with buy-and-bill rather than a pharmacy fill.
- Small inconsistencies between the two parallel forms are easy to introduce and hard to catch before submission.
How long an application takes
We do not publish a turnaround figure for Opdivo and Yervoy, because Bristol Myers Squibb sets it and it moves. What a practice can control is the work before submission. Four factors commonly affect the timeline: how long the patient section takes to return, how many review cycles occur between staff and the prescriber, whether the submission is complete on the first attempt, and the manufacturer review time, which we do not estimate.
How AlgoMeds handles it for Opdivo and Yervoy
AlgoMeds opens the correct current Opdivo form, including variant forms that depend on indication, already filled from the patient chart, prescriber profile, insurance on file and prior submitted applications. The patient signs from a single-use, identity-verified link sent by text message, with no account required. This can reduce printing and scanning. Required documents are checked before submission, the application is tracked to a decision, and renewals open ahead of expiry using information from the prior application.
For Opdivo and Yervoy, as for every program, AlgoMeds does not determine eligibility, predict approval, or claim to improve the odds of a decision going a particular way. It removes the paperwork between a clinical decision and a submittedOpdivo and Yervoy application, nothing more, and nothing that touches the manufacturer’s judgement.See the full coordinator workflow.
Opdivo and Yervoy patient assistance: frequently asked questions
Can a practice file one application for a patient on both Opdivo and Yervoy?
No. They are separate enrollments even though the form is the same document and both are Bristol Myers Squibb programs. Each requires its own completed and signed application. AlgoMeds carries the shared patient, prescriber and income data across both so the second does not repeat the first.
What happens if the combination course finishes before the application is approved?
That is a timing question for the manufacturer program, not something a software platform can promise around. Confirm retroactive handling directly with the program. What AlgoMeds does is remove the days lost to paperwork so the application is submitted sooner.
Related program guides
Practices working with this program may also work with these programs. See the full program directory, or theoncology overview.
Opdivo and Yervoy are registered trademarks of Bristol Myers Squibb or its affiliates. AlgoMeds is not affiliated with, endorsed by, or sponsored by Bristol Myers Squibb. Program details are subject to change. Confirm current requirements with the official program before applying.
This page is general information for medical practices about a manufacturer program. It is not medical advice, not legal advice, and not a determination of eligibility. AlgoMeds does not host or reproduce manufacturer enrollment forms on this website.
Stop retyping the Opdivo form.
Supported fields are filled from practice records, patients can sign from a text message, and staff can track each application from one workflow.